As of Dec 02
| -0.11 / -4.98%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +66.67% increase from the last price of 2.10.
The current consensus among 2 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.